rabbit polyclonal anti cd103  (Boster Bio)

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8 (x ± SEM) (A), CD4 (x ± SEM) (B), CD103 (x ± SEM) (C), CD49 (x ± SEM) (D), CD69 (x ± SEM) (E), CXCR6 (x ± SEM) (F), IL-17A (x ± SEM) (G) and IL-22 (x ± SEM) (H) in the lesional skin of patients ( n = 5, dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with anti-interleukin-17 (anti-IL-17) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different ( p < 0.05)

Article Snippet: Subsequently, they were incubated at 4°C overnight with mouse anti-CD8 and CD4 or rabbit anti-CD103, CD69, CD49, CXCR6, IL-17 and IL-22 polyclonal antibodies (1 : 50; Biorbyt, UK).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8 ( x ± SEM) (A), CD4 ( x ± SEM) (B), CD103 ( x ± SEM) (C), CD49 ( x ± SEM) (D), CD69 ( x ± SEM) (E), CXCR6 ( x ± SEM) (F), IL-17A ( x ± SEM) (G) and IL-22 ( x ± SEM) (H) in the lesional skin of patients ( n = 4), dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with anti-tumour necrosis factor α (TNF-α) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different ( p < 0.05)

Article Snippet: Subsequently, they were incubated at 4°C overnight with mouse anti-CD8 and CD4 or rabbit anti-CD103, CD69, CD49, CXCR6, IL-17 and IL-22 polyclonal antibodies (1 : 50; Biorbyt, UK).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8 ( x ± SEM) (A), CD4 ( x ± SEM) (B), CD103 ( x ± SEM) (C), CD49 ( x ± SEM) (D), CD69 ( x ± SEM) (E), CXCR6 ( x ± SEM) (F), IL-17A ( x ± SEM) (G) and IL-22 ( x ± SEM) (H) in the lesional skin of patients ( n = 4, dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with methotrexate (MTX) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different ( p < 0.05)

Article Snippet: Subsequently, they were incubated at 4°C overnight with mouse anti-CD8 and CD4 or rabbit anti-CD103, CD69, CD49, CXCR6, IL-17 and IL-22 polyclonal antibodies (1 : 50; Biorbyt, UK).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The skin location of CD8, CD4, CD103, CD49, CD69, CXCR6, IL-17A and IL-22 proteins (the representative sections) in the lesional skin (dermis and epidermis) for all the therapies. The proteins are marked in green (fluorescein). Magnification: 500×

Article Snippet: Subsequently, they were incubated at 4°C overnight with mouse anti-CD8 and CD4 or rabbit anti-CD103, CD69, CD49, CXCR6, IL-17 and IL-22 polyclonal antibodies (1 : 50; Biorbyt, UK).

Techniques:

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: Changes in the immunoreactive area (%) of CD8, CD4, CD103, CD49, CD69, CXCR6, IL-17A and IL-22 proteins in patients during therapy with: anti-interleukin-17 (anti-IL-17), anti-tumour necrosis factor α (anti-TNF-α), methotrexate (MTX) (week 0, 4 and 12). Bars with an asterisk show statistically significant differences (* p < 0.05)

Article Snippet: Subsequently, they were incubated at 4°C overnight with mouse anti-CD8 and CD4 or rabbit anti-CD103, CD69, CD49, CXCR6, IL-17 and IL-22 polyclonal antibodies (1 : 50; Biorbyt, UK).

Techniques:

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8 (x ± SEM) (A), CD4 (x ± SEM) (B), CD103 (x ± SEM) (C), CD49 (x ± SEM) (D), CD69 (x ± SEM) (E), CXCR6 (x ± SEM) (F), IL-17A (x ± SEM) (G) and IL-22 (x ± SEM) (H) in the lesional skin of patients ( n = 5, dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with anti-interleukin-17 (anti-IL-17) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different ( p < 0.05)

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8 ( x ± SEM) (A), CD4 ( x ± SEM) (B), CD103 ( x ± SEM) (C), CD49 ( x ± SEM) (D), CD69 ( x ± SEM) (E), CXCR6 ( x ± SEM) (F), IL-17A ( x ± SEM) (G) and IL-22 ( x ± SEM) (H) in the lesional skin of patients ( n = 4), dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with anti-tumour necrosis factor α (TNF-α) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different ( p < 0.05)

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8 ( x ± SEM) (A), CD4 ( x ± SEM) (B), CD103 ( x ± SEM) (C), CD49 ( x ± SEM) (D), CD69 ( x ± SEM) (E), CXCR6 ( x ± SEM) (F), IL-17A ( x ± SEM) (G) and IL-22 ( x ± SEM) (H) in the lesional skin of patients ( n = 4, dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with methotrexate (MTX) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different ( p < 0.05)

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The skin location of CD8, CD4, CD103, CD49, CD69, CXCR6, IL-17A and IL-22 proteins (the representative sections) in the lesional skin (dermis and epidermis) for all the therapies. The proteins are marked in green (fluorescein). Magnification: 500×

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques:

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: Changes in the immunoreactive area (%) of CD8, CD4, CD103, CD49, CD69, CXCR6, IL-17A and IL-22 proteins in patients during therapy with: anti-interleukin-17 (anti-IL-17), anti-tumour necrosis factor α (anti-TNF-α), methotrexate (MTX) (week 0, 4 and 12). Bars with an asterisk show statistically significant differences (* p < 0.05)

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques:

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The immunoreactive area (%) of CD8+CD103+ (x ± SEM) and CD4+CD103+ (x ± SEM) in the lesional skin of patients ( n = 5, dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with anti-interleukin-17 (anti-IL-17), anti-tumour necrosis factor α (anti-TNF-α), methotrexate (MTX) in comparison with healthy controls ( n = 10, dermis and epidermis). Bars with different letters are significantly different (p < 0.05)

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques: Comparison

Journal: Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

Article Title: The effect of therapy on TRM in psoriatic lesions

doi: 10.5114/ada.2021.113125

Figure Lengend Snippet: The skin location of CD8 (green – Alexa 488), CD4 (green – Alexa 488) and CD103 (red – Alexa 594) proteins (the representative sections) in the lesional skin of patients ( n = 5 or n = 4, dermis and epidermis) before (week 0) and during treatment (week 4 and week 12) with: anti-interleukin-17 (anti-IL-17), anti-tumour necrosis factor α (anti-TNF-α), methotrexate (MTX). Magnification: 500×

Article Snippet: During the analysis of CD4+CD103+ and CD8+CD103+, after being blocked with 2.5% normal goat serum for min, the frozen sections were incubated with the primary mouse anti-CD8 and -CD4 and rabbit anti-CD103 polyclonal antibody (1 : 50; Biorbyt, UK) and the secondary goat anti-mouse/rabbit antibodies (VectaFluor Duet Kit, X-Rabbit IgG/D488 X-Mouse IgG, Vector Laboratories, USA).

Techniques: